NEW YORK (TheStreet) -- Barclays downgraded C.R. Bard  (BCR) to "equal weight" from "overweight." The firm noted pressure on the company due to its exposure to the peripheral vascular space affected by the Medtronic  (MDT) deal with Covidien  (COV). 

The stock closed at $137.74 on Tuesday.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

BCR Chart

BCR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.